Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
One of the most frequent allelic deletions in
hepatocellular carcinoma
(
HCC
) has been found at chromosome 8p21-23. We reported here the identification and characterization of a novel gene for a
hepatocellular carcinoma related protein 1
(
HCRP1
) localized at 8p22, which was isolated by positional candidate cloning. The expression of the gene for
HCRP1
was most abundant in normal human liver tissue and significantly reduced or undetected in
HCC
tissues. The analysis of subcellular distribution showed that
HCRP1
diffused in the cytoplasm with a significant fraction accumulated in the nuclei. After introduction of the sense and antisense cDNA of
HCRP1
into
HCC
cell line SMMC-7721, we observed that the overexpression of
HCRP1
significantly inhibited both anchorage-dependent and anchorage-independent cell growth in vitro. Using the transgenic short hairpin RNA (shRNA) to knock down the expression of
HCRP1
gene in the other
HCC
cell line BEL-7404 resulted in the cell growth greatly enhanced. Moreover, reduction of the
HCRP1
gene expression could also elevate the invasive ability of BEL-7404 cells. Our results strongly suggest that
HCRP1
might be a growth inhibitory protein and associated with decreasing the invasion of
HCC
cells.
...
PMID:HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. 1462 89
Loss of
hepatocellular carcinoma
-related protein 1 (HCRP1) (alias
VPS37A
) plays a role in endocytosis of receptor tyrosine kinases as a member of the ESCRT complex and has been linked to poor patient outcome in various types of epithelial cancer. To this date, the molecular and biological mechanisms explaining how its absence would contribute to tumor progression remain unknown. Using genomic editing with CRISPR-Cas9, we generated ovarian and breast cancer cell lines with loss-of-function mutations of HCRP1. We hypothesized that pathways downstream of receptor tyrosine kinases such as epidermal growth factor receptor are affected by HCRP1 loss and looked for deregulated signaling using immunoblotting and classical cancer biology assays. In our study, we show that endogenous deletion of HCRP1 leads to elevated phosphorylation of the transcription factor Signal transducer and activator of transcription 3 (STAT3) and induces upregulation of PD-L1, an important regulator of immune checkpoint inhibition. HCRP1 loss further leads to a mesenchymal phenotype switch in cancer cells, leading to increased proliferation and migration. Concludingly, our data emphasize the role of the tumor microenvironment in tumors with low or absent HCRP1 expression and suggest HCRP1 loss as a potential marker for metastatic potential and immunogenicity of epidermal growth factor receptor-driven cancer.
...
PMID:Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. 3319 51